{"nctId":"NCT02135029","briefTitle":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins","startDateStruct":{"date":"2014-06","type":"ACTUAL"},"conditions":["Hyperlipidemia"],"count":184,"armGroups":[{"label":"Bococizumab (PF-04950615;RN316)","type":"EXPERIMENTAL","interventionNames":["Drug: Bococizumab (PF-04950615;RN316)"]},{"label":"Atorvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo for Bococizumab (PF-04950615;RN316)","Other: Placebo for atorvastatin"]}],"interventions":[{"name":"Bococizumab (PF-04950615;RN316)","otherNames":[]},{"name":"Atorvastatin","otherNames":[]},{"name":"Placebo for Bococizumab (PF-04950615;RN316)","otherNames":[]},{"name":"Placebo for atorvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hyperlipidemia\n* Statin Intolerant\n* Fasting LDL-C \\> = 70 mg/dL Fasting TG \\< = 400 mg/dL\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding females\n* Cardiovascular or cerebrovascular event or procedure within 90 days\n* Severe or life-threatening adverse events with past use of statins\n* Poorly controlled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"12.86"},{"groupId":"OG001","value":"-52.0","spread":"22.75"},{"groupId":"OG002","value":"-32.6","spread":"20.98"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Total Cholesterol (TC) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"9.92"},{"groupId":"OG001","value":"-37.0","spread":"17.08"},{"groupId":"OG002","value":"-25.7","spread":"16.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"11.77"},{"groupId":"OG001","value":"-31.2","spread":"21.31"},{"groupId":"OG002","value":"-26.8","spread":"16.64"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"11.64"},{"groupId":"OG001","value":"-46.0","spread":"22.19"},{"groupId":"OG002","value":"-27.2","spread":"18.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"13.34"},{"groupId":"OG001","value":"-39.1","spread":"26.85"},{"groupId":"OG002","value":"-28.1","spread":"20.20"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"11.16"},{"groupId":"OG001","value":"-50.0","spread":"21.06"},{"groupId":"OG002","value":"-32.5","spread":"21.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"14.46"},{"groupId":"OG001","value":"-41.9","spread":"26.00"},{"groupId":"OG002","value":"-34.0","spread":"21.14"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"33.13"},{"groupId":"OG001","value":"-21.5","spread":"39.77"},{"groupId":"OG002","value":"5.1","spread":"29.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"34.59"},{"groupId":"OG001","value":"-16.6","spread":"31.71"},{"groupId":"OG002","value":"4.1","spread":"31.33"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"12.31"},{"groupId":"OG001","value":"13.2","spread":"19.73"},{"groupId":"OG002","value":"0.4","spread":"13.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"12.34"},{"groupId":"OG001","value":"11.5","spread":"18.84"},{"groupId":"OG002","value":"0.2","spread":"14.02"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"15.62"},{"groupId":"OG001","value":"-42.7","spread":"29.50"},{"groupId":"OG002","value":"-33.3","spread":"20.91"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"26.77"},{"groupId":"OG001","value":"-12.5","spread":"27.42"},{"groupId":"OG002","value":"-20.7","spread":"23.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"30.01"},{"groupId":"OG001","value":"-13.6","spread":"40.58"},{"groupId":"OG002","value":"-21.9","spread":"30.19"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"11.38"},{"groupId":"OG001","value":"8.0","spread":"14.94"},{"groupId":"OG002","value":"-2.8","spread":"11.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"11.91"},{"groupId":"OG001","value":"8.0","spread":"14.66"},{"groupId":"OG002","value":"-2.2","spread":"11.66"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"10.83"},{"groupId":"OG001","value":"4.1","spread":"13.45"},{"groupId":"OG002","value":"-3.2","spread":"12.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"12.80"},{"groupId":"OG001","value":"3.9","spread":"13.21"},{"groupId":"OG002","value":"-0.6","spread":"19.96"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"26.77"},{"groupId":"OG001","value":"-12.5","spread":"27.42"},{"groupId":"OG002","value":"-20.7","spread":"23.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"30.01"},{"groupId":"OG001","value":"-13.6","spread":"40.58"},{"groupId":"OG002","value":"-21.9","spread":"30.19"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.1","spread":"46.96"},{"groupId":"OG001","value":"168.8","spread":"47.31"},{"groupId":"OG002","value":"169.9","spread":"46.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"21.12"},{"groupId":"OG001","value":"-88.0","spread":"43.82"},{"groupId":"OG002","value":"-56.5","spread":"40.68"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"262.3","spread":"51.20"},{"groupId":"OG001","value":"250.1","spread":"54.50"},{"groupId":"OG002","value":"256.2","spread":"53.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"25.46"},{"groupId":"OG001","value":"-93.8","spread":"47.94"},{"groupId":"OG002","value":"-67.7","spread":"46.85"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":"13.92"},{"groupId":"OG001","value":"51.1","spread":"15.02"},{"groupId":"OG002","value":"55.7","spread":"13.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"6.31"},{"groupId":"OG001","value":"6.0","spread":"8.01"},{"groupId":"OG002","value":"-0.5","spread":"7.07"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210.7","spread":"49.75"},{"groupId":"OG001","value":"199.2","spread":"50.40"},{"groupId":"OG002","value":"200.5","spread":"50.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"22.69"},{"groupId":"OG001","value":"-99.8","spread":"46.99"},{"groupId":"OG002","value":"-67.1","spread":"45.59"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Triglycerides (TG) at Week 12","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133.3","spread":"27.00"},{"groupId":"OG001","value":"125.8","spread":"31.43"},{"groupId":"OG002","value":"124.6","spread":"29.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"15.08"},{"groupId":"OG001","value":"-57.5","spread":"28.57"},{"groupId":"OG002","value":"-35.3","spread":"25.66"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Lipoprotein (A) (Lp[A]) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":"38.46"},{"groupId":"OG001","value":"27.1","spread":"36.31"},{"groupId":"OG002","value":"31.7","spread":"38.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"5.19"},{"groupId":"OG001","value":"-5.8","spread":"7.93"},{"groupId":"OG002","value":"1.9","spread":"5.27"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Total Cholesterol (TC)/ High Density Lipoprotein Cholesterol (HDL-C) Ratio at Weeks 12 and 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.53"},{"groupId":"OG001","value":"5.2","spread":"1.45"},{"groupId":"OG002","value":"4.8","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.76"},{"groupId":"OG001","value":"-2.3","spread":"1.13"},{"groupId":"OG002","value":"-1.3","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.77"},{"groupId":"OG001","value":"-2.0","spread":"1.35"},{"groupId":"OG002","value":"-1.3","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB)/Apolipoprotein A-I (ApoA-I) Ratio at Weeks 12 And 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.25"},{"groupId":"OG001","value":"0.9","spread":"0.24"},{"groupId":"OG002","value":"0.8","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.10"},{"groupId":"OG001","value":"-0.4","spread":"0.21"},{"groupId":"OG002","value":"-0.2","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.12"},{"groupId":"OG001","value":"-0.4","spread":"0.25"},{"groupId":"OG002","value":"-0.2","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"71.8","spread":null},{"groupId":"OG002","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"61.4","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"45.1","spread":null},{"groupId":"OG002","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"41.4","spread":null},{"groupId":"OG002","value":"15.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma PF-04950615 Concentrations at Weeks 12 and 24","description":"Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLOQ =0.4 micrograms per milliliter \\[mcg/mL\\]) to zero. Participants who received PF-04950615 150 mg were evaluable for this outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.21","spread":"9.309"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.38","spread":"7.890"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events Related to Type 1 and 3 Hypersensitivity Reactions, Injection Site Reactions, Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb)","description":"Participants with at least one positive ADA titer greater than or equal to (\\>=) 6.23 or positive nAb titer \\>=4.32 were reported. Titers are expressed as log2 reciprocal dilution at assay cutpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-drug Antibody (ADA) and Neutralizing Anti-body (nAb) Titer Level in Participants Who Tested Positive for ADA and nAb Respectively","description":"Titer levels of participants who tested positive for ADA and nAb are reported. Titers are expressed as log2 reciprocal dilution at assay cutpoint.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.94","spread":"1.181"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.49","spread":"1.646"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":"2.196"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.12","spread":"2.981"}]}]},{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":"2.440"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.28","spread":"1.358"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.09","spread":"2.135"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinued Due to Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.10"},{"groupId":"OG001","value":"10.8","spread":"0.21"},{"groupId":"OG002","value":"16.7","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.12"},{"groupId":"OG001","value":"0","spread":"0.25"},{"groupId":"OG002","value":"0","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":73},"commonTop":["Myalgia","Muscle spasms","Injection site reaction","Fatigue","Arthralgia"]}}}